- Home
- GHRS vs PAXS Comparison
GHRS vs PAXS Comparison
Compare GHRS & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- PAXS
- Stock Information
- Founded
- GHRS 2018
- PAXS 2021
- Country
- GHRS Ireland
- PAXS United States
- Employees
- GHRS N/A
- PAXS N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- GHRS Health Care
- PAXS Finance
- Exchange
- GHRS Nasdaq
- PAXS Nasdaq
- Market Cap
- GHRS 737.5M
- PAXS 677.7M
- IPO Year
- GHRS 2021
- PAXS N/A
- Fundamental
- Price
- GHRS $14.76
- PAXS $15.15
- Analyst Decision
- GHRS Strong Buy
- PAXS
- Analyst Count
- GHRS 8
- PAXS 0
- Target Price
- GHRS $30.63
- PAXS N/A
- AVG Volume (30 Days)
- GHRS 204.8K
- PAXS 195.0K
- Earning Date
- GHRS 05-08-2025
- PAXS 01-01-0001
- Dividend Yield
- GHRS N/A
- PAXS 11.72%
- EPS Growth
- GHRS N/A
- PAXS N/A
- EPS
- GHRS N/A
- PAXS N/A
- Revenue
- GHRS N/A
- PAXS N/A
- Revenue This Year
- GHRS N/A
- PAXS N/A
- Revenue Next Year
- GHRS N/A
- PAXS N/A
- P/E Ratio
- GHRS N/A
- PAXS N/A
- Revenue Growth
- GHRS N/A
- PAXS N/A
- 52 Week Low
- GHRS $6.00
- PAXS $12.57
- 52 Week High
- GHRS $20.50
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- GHRS 66.16
- PAXS 53.73
- Support Level
- GHRS $11.82
- PAXS $15.05
- Resistance Level
- GHRS $12.94
- PAXS $15.23
- Average True Range (ATR)
- GHRS 0.99
- PAXS 0.11
- MACD
- GHRS 0.19
- PAXS 0.02
- Stochastic Oscillator
- GHRS 84.53
- PAXS 75.76
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.